1. Scrip
  2. >>Archive

Lion Bioscience AG

 
• By Wendy Diller

Drug Discovery Tools; Bioinformatics; Genomics. Lion Bioscience will offer bioinformatics and sequencing services based on modules. It offers an automated sequencing module, which claims higher throughput, higher reading lengths per clone and greater accuracy than commercially available systems. Lion also offers computational sequence anlysis software.

Last year, several scientists from the European Molecular Biology Laboratories(EMBL), a research organization in Heidelberg, Germany which supports 15 European states, were mulling over the idea of commercializing its bioinformatics work. At about the same time, a different group from the same scientific research organization was looking for ways to commercialize its sequencing technology. Yet another group, outside EMBL, planned to start a company in the field of genomics. The three parties began to talk and agreed to join forces. Lion Bioscience AG was born this winter to offer bioinformatics and sequencing services to pharmaceutical and industrial corporations and scientific research organizations. Lion is the first start-up built around EMBL technologies.

The founders were convinced that the combined groups would be in a better position to cover the full spectrum of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Obesity Treatment Could Go Global With Lilly’s Orforglipron

 
• By Andrew McConaghie

The company’s oral GLP-1 candidate has reassured on its safety at the American Diabetes Association meeting, convincing analysts it will open up new global markets.